These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28676345)

  • 21. Classification of Alzheimer's disease and prediction of mild cognitive impairment-to-Alzheimer's conversion from structural magnetic resource imaging using feature ranking and a genetic algorithm.
    Beheshti I; Demirel H; Matsuda H;
    Comput Biol Med; 2017 Apr; 83():109-119. PubMed ID: 28260614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal Neuroimaging Hippocampal Markers for Diagnosing Alzheimer's Disease.
    Platero C; Lin L; Tobar MC
    Neuroinformatics; 2019 Jan; 17(1):43-61. PubMed ID: 29785624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Nonparametric Approach for Mild Cognitive Impairment to AD Conversion Prediction: Results on Longitudinal Data.
    Minhas S; Khanum A; Riaz F; Alvi A; Khan SA
    IEEE J Biomed Health Inform; 2017 Sep; 21(5):1403-1410. PubMed ID: 28113683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and Temporal Characterization of Features Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease.
    Martinez-Torteya A; Gomez-Rueda H; Trevino V; Farber J; Tamez-Pena J; For The Alzheimer's Disease Neuroimaging Initiative
    Curr Alzheimer Res; 2018; 15(8):751-763. PubMed ID: 29422002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome.
    Guo LH; Alexopoulos P; Eisele T; Wagenpfeil S; Kurz A; Perneczky R
    Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):325-33. PubMed ID: 22932720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment.
    Grimmer T; Wutz C; Drzezga A; Förster S; Förstl H; Ortner M; Perneczky R; Kurz A
    Curr Alzheimer Res; 2013 Jan; 10(1):82-5. PubMed ID: 23036071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting Alzheimer's conversion in mild cognitive impairment patients using longitudinal neuroimaging and clinical markers.
    Platero C; Tobar MC;
    Brain Imaging Behav; 2021 Aug; 15(4):1728-1738. PubMed ID: 33169305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discriminating Alzheimer's disease progression using a new hippocampal marker from T1-weighted MRI: The local surface roughness.
    Platero C; López ME; Carmen Tobar MD; Yus M; Maestu F
    Hum Brain Mapp; 2019 Apr; 40(5):1666-1676. PubMed ID: 30451343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease.
    Cavedo E; Suppa P; Lange C; Opfer R; Lista S; Galluzzi S; Schwarz AJ; Spies L; Buchert R; Hampel H; ;
    J Alzheimers Dis; 2017; 60(1):151-164. PubMed ID: 28777748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.
    Rhodius-Meester HF; Koikkalainen J; Mattila J; Teunissen CE; Barkhof F; Lemstra AW; Scheltens P; Lötjönen J; van der Flier WM
    J Alzheimers Dis; 2016; 50(1):261-70. PubMed ID: 26577521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
    Choo IH; Ni R; Schöll M; Wall A; Almkvist O; Nordberg A
    J Alzheimers Dis; 2013; 33(4):929-39. PubMed ID: 23047371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort.
    Prasad K; Wiryasaputra L; Ng A; Kandiah N
    Dement Geriatr Cogn Disord; 2011; 31(6):431-4. PubMed ID: 21757908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of clinical and biomarker conformed Alzheimer's disease and mild cognitive impairment from multi-feature brain structural MRI using age-correction from a large independent lifespan sample.
    Li B; Zhang M; Riphagen J; Morrison Yochim K; Li B; Liu J; Salat DH;
    Neuroimage Clin; 2020; 28():102387. PubMed ID: 32871388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study.
    Brueggen K; Dyrba M; Barkhof F; Hausner L; Filippi M; Nestor PJ; Hauenstein K; Klöppel S; Grothe MJ; Kasper E; Teipel SJ
    J Alzheimers Dis; 2015; 48(1):197-204. PubMed ID: 26401940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.
    Falahati F; Ferreira D; Muehlboeck JS; Eriksdotter M; Simmons A; Wahlund LO; Westman E
    Neuroimage Clin; 2017; 16():418-428. PubMed ID: 28879083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression.
    Teipel SJ; Kurth J; Krause B; Grothe MJ;
    Neuroimage Clin; 2015; 8():583-93. PubMed ID: 26199870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.